Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome

Yusuke Murata, Daisuke Kobayashi, Nanae Imuta, Koichi Haraguchi, Ichiro Ieiri, Ryoji Nishimura, Susumu Koyama, Kazunori Mine

研究成果: ジャーナルへの寄稿記事

17 引用 (Scopus)

抄録

Paroxetine discontinuation symptoms can at times be severe enough to reduce the quality of life. However, it is currently not possible to predict the occurrence of discontinuation syndrome before the initiation or discontinuation of paroxetine treatment. In this study, we investigated the effects of genetic polymorphisms in the serotonin 1A, 2A, 2C, 3A, and 3B receptor, the serotonin transporter, and the cytochrome P450 2D6 (CYP2D6) genes on the occurrence of paroxetine discontinuation syndrome. A consecutive series of 56 Japanese patients who had a diagnosis of major depressive or anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were treated with paroxetine. Paroxetine discontinuation syndrome was found in 35.7% of the patients by direct interview. Patients who stopped taking paroxetine abruptly experienced paroxetine discontinuation syndrome significantly more often than patients who had a tapering off of the dosage of medication. Patients who had the-1019C allele experienced paroxetine discontinuation syndrome more frequently than patients who had the-1019G homozygote (nominal P = 0.0423) of the serotonin 1A receptor gene. However, this result did not remain significant after the Bonferroni correction for multiple comparisons. The findings suggest that the abrupt stoppage of medication is a major risk factor for the occurrence of paroxetine discontinuation syndrome and that C(-1019)G polymorphism of the serotonin 1A receptor gene may be related to the occurrence of the syndrome.

元の言語英語
ページ(範囲)11-17
ページ数7
ジャーナルJournal of Clinical Psychopharmacology
30
発行部数1
DOI
出版物ステータス出版済み - 2 1 2010

Fingerprint

Paroxetine
Serotonin Plasma Membrane Transport Proteins
Serotonin
Genes
Receptor, Serotonin, 5-HT1A
Cytochrome P-450 CYP2D6
Major Depressive Disorder
Homozygote
Genetic Polymorphisms
Anxiety Disorders
Diagnostic and Statistical Manual of Mental Disorders
Alleles
Quality of Life
Interviews

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)

これを引用

Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. / Murata, Yusuke; Kobayashi, Daisuke; Imuta, Nanae; Haraguchi, Koichi; Ieiri, Ichiro; Nishimura, Ryoji; Koyama, Susumu; Mine, Kazunori.

:: Journal of Clinical Psychopharmacology, 巻 30, 番号 1, 01.02.2010, p. 11-17.

研究成果: ジャーナルへの寄稿記事

Murata, Yusuke ; Kobayashi, Daisuke ; Imuta, Nanae ; Haraguchi, Koichi ; Ieiri, Ichiro ; Nishimura, Ryoji ; Koyama, Susumu ; Mine, Kazunori. / Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. :: Journal of Clinical Psychopharmacology. 2010 ; 巻 30, 番号 1. pp. 11-17.
@article{b70a9a919fae42ffbdb85822ed529114,
title = "Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome",
abstract = "Paroxetine discontinuation symptoms can at times be severe enough to reduce the quality of life. However, it is currently not possible to predict the occurrence of discontinuation syndrome before the initiation or discontinuation of paroxetine treatment. In this study, we investigated the effects of genetic polymorphisms in the serotonin 1A, 2A, 2C, 3A, and 3B receptor, the serotonin transporter, and the cytochrome P450 2D6 (CYP2D6) genes on the occurrence of paroxetine discontinuation syndrome. A consecutive series of 56 Japanese patients who had a diagnosis of major depressive or anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were treated with paroxetine. Paroxetine discontinuation syndrome was found in 35.7{\%} of the patients by direct interview. Patients who stopped taking paroxetine abruptly experienced paroxetine discontinuation syndrome significantly more often than patients who had a tapering off of the dosage of medication. Patients who had the-1019C allele experienced paroxetine discontinuation syndrome more frequently than patients who had the-1019G homozygote (nominal P = 0.0423) of the serotonin 1A receptor gene. However, this result did not remain significant after the Bonferroni correction for multiple comparisons. The findings suggest that the abrupt stoppage of medication is a major risk factor for the occurrence of paroxetine discontinuation syndrome and that C(-1019)G polymorphism of the serotonin 1A receptor gene may be related to the occurrence of the syndrome.",
author = "Yusuke Murata and Daisuke Kobayashi and Nanae Imuta and Koichi Haraguchi and Ichiro Ieiri and Ryoji Nishimura and Susumu Koyama and Kazunori Mine",
year = "2010",
month = "2",
day = "1",
doi = "10.1097/JCP.0b013e3181c8ae80",
language = "English",
volume = "30",
pages = "11--17",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome

AU - Murata, Yusuke

AU - Kobayashi, Daisuke

AU - Imuta, Nanae

AU - Haraguchi, Koichi

AU - Ieiri, Ichiro

AU - Nishimura, Ryoji

AU - Koyama, Susumu

AU - Mine, Kazunori

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Paroxetine discontinuation symptoms can at times be severe enough to reduce the quality of life. However, it is currently not possible to predict the occurrence of discontinuation syndrome before the initiation or discontinuation of paroxetine treatment. In this study, we investigated the effects of genetic polymorphisms in the serotonin 1A, 2A, 2C, 3A, and 3B receptor, the serotonin transporter, and the cytochrome P450 2D6 (CYP2D6) genes on the occurrence of paroxetine discontinuation syndrome. A consecutive series of 56 Japanese patients who had a diagnosis of major depressive or anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were treated with paroxetine. Paroxetine discontinuation syndrome was found in 35.7% of the patients by direct interview. Patients who stopped taking paroxetine abruptly experienced paroxetine discontinuation syndrome significantly more often than patients who had a tapering off of the dosage of medication. Patients who had the-1019C allele experienced paroxetine discontinuation syndrome more frequently than patients who had the-1019G homozygote (nominal P = 0.0423) of the serotonin 1A receptor gene. However, this result did not remain significant after the Bonferroni correction for multiple comparisons. The findings suggest that the abrupt stoppage of medication is a major risk factor for the occurrence of paroxetine discontinuation syndrome and that C(-1019)G polymorphism of the serotonin 1A receptor gene may be related to the occurrence of the syndrome.

AB - Paroxetine discontinuation symptoms can at times be severe enough to reduce the quality of life. However, it is currently not possible to predict the occurrence of discontinuation syndrome before the initiation or discontinuation of paroxetine treatment. In this study, we investigated the effects of genetic polymorphisms in the serotonin 1A, 2A, 2C, 3A, and 3B receptor, the serotonin transporter, and the cytochrome P450 2D6 (CYP2D6) genes on the occurrence of paroxetine discontinuation syndrome. A consecutive series of 56 Japanese patients who had a diagnosis of major depressive or anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were treated with paroxetine. Paroxetine discontinuation syndrome was found in 35.7% of the patients by direct interview. Patients who stopped taking paroxetine abruptly experienced paroxetine discontinuation syndrome significantly more often than patients who had a tapering off of the dosage of medication. Patients who had the-1019C allele experienced paroxetine discontinuation syndrome more frequently than patients who had the-1019G homozygote (nominal P = 0.0423) of the serotonin 1A receptor gene. However, this result did not remain significant after the Bonferroni correction for multiple comparisons. The findings suggest that the abrupt stoppage of medication is a major risk factor for the occurrence of paroxetine discontinuation syndrome and that C(-1019)G polymorphism of the serotonin 1A receptor gene may be related to the occurrence of the syndrome.

UR - http://www.scopus.com/inward/record.url?scp=74549198246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549198246&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e3181c8ae80

DO - 10.1097/JCP.0b013e3181c8ae80

M3 - Article

VL - 30

SP - 11

EP - 17

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 1

ER -